Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

Impact · against what's priced in

The article provides no fundamental catalysts for BioCryst, merely aggregating existing analyst price targets and consensus earnings revisions. Since these are lagging indicators typically already reflected in the current valuation, the news is not a driver for the stock price.

BCRX+0.00: No priced-in read yet

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

What matters in this story

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

What matters in this story

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade

How each ticker is affected

Track these names every morning.

Wall Street Analysts Believe Leonardo DRS, Inc. (DRS) Could Rally 32.44%: Here's is How to Trade

Does ExlService Holdings (EXLS) Have the Potential to Rally 45.38% as Wall Street Analysts Expect?

Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

What matters in this story

Next reads from the same story arc

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

What matters in this story

Next reads from the same story arc

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade

How each ticker is affected

Track these names every morning.

Wall Street Analysts Believe Leonardo DRS, Inc. (DRS) Could Rally 32.44%: Here's is How to Trade

Does ExlService Holdings (EXLS) Have the Potential to Rally 45.38% as Wall Street Analysts Expect?

Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?